MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial

14.03.2023 - -   Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 -   Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating safety and ...

Related Keywords

United States , Ireland , United Kingdom , London , City Of , American , Jason Braco , Botaretigene Sparoparvovec , American Academy Of Ophthalmology Annual Meeting , Lifesci Communications , Meiragtx Holdings , European Society Of Gene , Janssen Pharmaceuticals Inc , Janssen Pharmaceutical Companies Of Johnson , Nasdaq , Alexandria Forbes , European Society , Cell Therapy , Annual Congress , Lumeos Phase , Development Highlights , Retina Subspecialty Day , Janssen Pharmaceuticals , Janssen Pharmaceutical Companies , Induced Xerostomia , Patient Reported Outcome , Global Rate , Xerostomia Questionnaire , Gene Regulation Platform , Vector Engineering , Therapy Manufacturing , Quality Control , Private Securities Litigation Reform Act , Annual Report , Gene Therapy Trial , X Linked Retinitis Pigmentosa , Ophthalmology Annual , Years Ended December ,